In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Zimonjic, Drazen B ^a   Chan, Lai N ^b   Tripathi, Veenu ^a   Lu, Jie ^b   Kwon, Ohyun ^c   Popescu, Nicholas C ^a   Lowy, Douglas R ^a   Tamanoi, Fuyuhiko ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Deleted in liver cancer 1; Geranylgeranyltransferase I inhibitor; Lung cancer; P61A6; RhoA

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN D2; GERANYLGERANYLTRANSFERASE 1; GERANYLTRANSFERASE; P 61A6; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; ENZYME INHIBITOR; GERANYLGERANYLTRANSFERASE TYPE-I; P61A6 COMPOUND; PHENYLALANINE; SULFONAMIDE; TRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER CELL; CANCER INHIBITION; CELL ANCHORAGE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SPECIFICITY; ENZYME ACTIVATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MEMBRANE BINDING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; ENZYMOLOGY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PRENYLATION; TUMOR CELL LINE;

ALKYL AND ARYL TRANSFERASES; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN D2; ENZYME INHIBITORS; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHENYLALANINE; PRENYLATION; RHOA GTP-BINDING PROTEIN; SULFONAMIDES;

EID: 84876741302     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-198     Document Type: Article

References (39)

1. Gelb MH, Brunsveld L, Hrycyna CA, Michaelis S, Tamanoi F, Van Voorhis WC, Waldmann H. Therapeutic intervention based on protein prenylation and associated modifications. Nat Chem Biol 2006, 2:518-528. 10.1038/nchembio818, 2892741, 16983387.
2. Berndt N, Hamilton A, Sebti S. Geranylgeranyltransferase-I inhibitors. Enzymes 2011, 129-163. Amsterdam: Academic Press/Elsevier, Hrycyna C, Bergo M, Tamanoi F.
3. Chan L, Watanabe M, Kwon O, Tamanoi F. Small-molecule inhibitors of GGTase-I from the heterocycle library derived from phosphine catalysis. Enzymes 2011, 165-177. Amsterdam: Academic Press/Elsevier, Hrycyna C, Bergo M, Tamanoi F.
4. Sjogren AK, Andersson KM, Liu M, Cutts BA, Karlsson C, Wahlstrom AM, Dalin M, Weinbaum C, Casey PJ, Tarkowski A, Swolin B, Young SG, Bergo MO. GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J Clin Invest 2007, 117:1294-1304. 10.1172/JCI30868, 1857236, 17476360.
5. Jaffe AB, Hall A. Rho GTPases in transformation and metastasis. Adv Cancer Res 2002, 84:57-80.
6. Lim KH, Baines AT, Fiordalisi JJ, Shipitsin M, Feig LA, Cox AD, Der CJ, Counter CM. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Canc Cell 2005, 7:533-545.
7. Lim KH, O'Hayer K, Adam SJ, Kendall SD, Campbell PM, Der CJ, Counter CM. Divergent Roles for RalA and RalB in Malignant Growth of Human Pancreatic Carcinoma Cells. Curr Biol 2006, 16:2385-2394. 10.1016/j.cub.2006.10.023, 17174914.
8. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett 2008, 582:2093-2101. 10.1016/j.febslet.2008.04.039, 18460342.
9. Lerner EC, Qian Y, Hamilton AD, Sebti SM. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem 1995, 270:26770-26773. 10.1074/jbc.270.45.26770, 7592913.
10. Peterson YK, Kelly P, Weinbaum CA, Casey PJ. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. J Biol Chem 2006, 281:12445-12450. 10.1074/jbc.M600168200, 16517596.
11. Castellano S, Fiji HD, Kinderman SS, Watanabe M, Leon P, Tamanoi F, Kwon O. Small-molecule inhibitors of protein geranylgeranyltransferase type I. J Am Chem Soc 2007, 129:5843-5845. 10.1021/ja070274n, 2543057, 17439124.
12. Chan LN, Fiji HD, Watanabe M, Kwon O, Tamanoi F. Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I. PLoS One 2011, 6:e26135. 10.1371/journal.pone.0026135, 3196516, 22028818.
13. Lu J, Chan L, Fiji HD, Dahl R, Kwon O, Tamanoi F. In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Mol Cancer Ther 2009, 8:1218-1226. 10.1158/1535-7163.MCT-08-1122, 2888841, 19417142.
14. Watanabe M, Fiji HD, Guo L, Chan L, Kinderman SS, Slamon DJ, Kwon O, Tamanoi F. Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J Biol Chem 2008, 283:9571-9579. 10.1074/jbc.M706229200, 2442295, 18230616.
15. Cancer Facts and Figures 2012 2012, http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf.
16. Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med 2012, 13:287-297.
17. Lahoz A, Hall A. DLC1: a significant GAP in the cancer genome. Genes Dev 2008, 22:1724-1730. 10.1101/gad.1691408, 2732422, 18593873.
18. Ullmannova V, Popescu NC. Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors. Int J Oncol 2006, 29:1127-1132.
19. Yuan BZ, Jefferson AM, Baldwin KT, Thorgeirsson SS, Popescu NC, Reynolds SH. DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene 2004, 23:1405-1411. 10.1038/sj.onc.1207291, 14661059.
20. Durkin ME, Avner MR, Huh CG, Yuan BZ, Thorgeirsson SS, Popescu NC. DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Lett 2005, 579:1191-1196. 10.1016/j.febslet.2004.12.090, 15710412.
21. Xue W, Krasnitz A, Lucito R, Sordella R, Vanaelst L, Cordon-Cardo C, Singer S, Kuehnel F, Wigler M, Powers S, Zender L, Lowe SW. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev 2008, 22:1439-1444. 10.1101/gad.1672608, 2418580, 18519636.
22. Healy KD, Hodgson L, Kim TY, Shutes A, Maddileti S, Juliano RL, Hahn KM, Harden TK, Bang YJ, Der CJ. DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. Mol Carcinog 2008, 47:326-337. 10.1002/mc.20389, 2679972, 17932950.
23. Qian X, Li G, Asmussen HK, Asnaghi L, Vass WC, Braverman R, Yamada KM, Popescu NC, Papageorge AG, Lowy DR. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci USA 2007, 104:9012-9017. 10.1073/pnas.0703033104, 1868654, 17517630.
24. Kato-Stankiewicz J, Hakimi I, Zhi G, Zhang J, Serebriiskii I, Guo L, Edamatsu H, Koide H, Menon S, Eckl R, Sakamuri S, Lu Y, Chen QZ, Agarwal S, Baumbach WR, Golemis EA, Tamanoi F, Khazak V. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc Natl Acad Sci USA 2002, 99:14398-14403. 10.1073/pnas.222222699, 137895, 12391290.
25. Croft DR, Olson MF. The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol Cell Biol 2006, 26:4612-4627. 10.1128/MCB.02061-05, 1489131, 16738326.
26. Watts KL, Cottrell E, Hoban PR, Spiteri MA. RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis. Respir Res 2006, 7:88. 10.1186/1465-9921-7-88, 1513217, 16776827.
27. Allal C, Pradines A, Hamilton AD, Sebti SM, Favre G. Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298. Cell Cycle 2002, 1:430-437. 10.4161/cc.1.6.272, 12548020.
28. Falsetti SC, Wang DA, Peng H, Carrico D, Cox AD, Der CJ, Hamilton AD, Sebti SM. Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth. Mol Cell Biol 2007, 27:8003-8014. 10.1128/MCB.00057-07, 2169159, 17875936.
29. Joyce PL, Cox AD. Rac1 and Rac3 are targets for geranylgeranyltransferase I inhibitor-mediated inhibition of signaling, transformation, and membrane ruffling. Cancer Res 2003, 63:7959-7967.
30. Vogt A, Sun J, Qian Y, Hamilton AD, Sebti SM. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem 1997, 272:27224-27229. 10.1074/jbc.272.43.27224, 9341167.
31. Huang H, Hu YD, Li N, Zhu Y. Inhibition of tumor growth and metastasis by non-small cell lung cancer cells transfected with cyclin D1-targeted siRNA. Oligonucleotides 2009, 19:151-162. 10.1089/oli.2008.0174, 2948454, 19355812.
32. Sakamoto T, Ishibashi T, Sugimoto K, Sakamoto N, Ohkawara H, Niinuma M, Nagata K, Kamioka M, Sugimoto N, Watanabe A, Kurabayashi M, Takuwa Y, Maruyama Y. RhoA-dependent PAI-1 gene expression induced in endothelial cells by monocyte adhesion mediates geranylgeranyl transferase I and Ca2+ signaling. Atherosclerosis 2007, 193:44-54. 10.1016/j.atherosclerosis.2006.08.036, 16973169.
33. Ohkawara H, Ishibashi T, Sakamoto T, Sugimoto K, Nagata K, Yokoyama K, Sakamoto N, Kamioka M, Matsuoka I, Fukuhara S, Sugimoto N, Takuwa Y, Maruyama Y. Thrombin-induced Rapid Geranylgeranylation of RhoA as an Essential Process for RhoA Activation in Endothelial Cells. J Biol Chem 2005, 280:10182-10188. 10.1074/jbc.M409547200, 15640525.
34. Laezza C, Pisanti S, Malfitano AM, Bifulco M. The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway. Endocr Relat Cancer 2008, 15:965-974. 10.1677/ERC-08-0030, 18676619.
35. Khan OM, Akula MK, Skalen K, Karlsson C, Stahlman M, Young SG, Boren J, Bergo MO. Targeting GGTase-I Activates RHOA, Increases Macrophage Reverse Cholesterol Transport, and Reduces Atherosclerosis in Mice. Circulation 2013, 127:782-790. 10.1161/CIRCULATIONAHA.112.000588, 23334894.
36. Khan OM, Ibrahim MX, Jonsson IM, Karlsson C, Liu M, Sjogren AK, Olofsson FJ, Brisslert M, Andersson S, Ohlsson C, Hulten LM, Bokarewa M, Bergo MO. Geranylgeranyltransferase type I (GGTase-I) deficiency hyperactivates macrophages and induces erosive arthritis in mice. J Clin Invest 2011, 121:628-639. 10.1172/JCI43758, 3026725, 21266780.
37. Yang XY, Guan M, Vigil D, Der CJ, Lowy DR, Popescu NC. p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. Oncogene 2009, 28:1401-1409. 10.1038/onc.2008.498, 2715999, 19151751.
38. Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. Nat Rev Cancer 2010, 10:842-857. 10.1038/nrc2960, 3124093, 21102635.
39. Du X, Qian X, Papageorge A, Schetter AJ, Vass WC, Liu X, Braverman R, Robles AI, Lowy DR. Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells. Cancer Res 2012, 72:4405-4416. 10.1158/0008-5472.CAN-12-0777, 22693251.